CN113769073A - Method for treating fundus hemorrhage by using biological enzyme - Google Patents

Method for treating fundus hemorrhage by using biological enzyme Download PDF

Info

Publication number
CN113769073A
CN113769073A CN202111203395.1A CN202111203395A CN113769073A CN 113769073 A CN113769073 A CN 113769073A CN 202111203395 A CN202111203395 A CN 202111203395A CN 113769073 A CN113769073 A CN 113769073A
Authority
CN
China
Prior art keywords
biological enzyme
fundus
fundus hemorrhage
hemorrhage
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111203395.1A
Other languages
Chinese (zh)
Inventor
王宁利
杨宗鑫
田磊
杜丽华
陈春辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Xinwei Low Carbon Technology R&d Co ltd
Original Assignee
Hangzhou Xinwei Low Carbon Technology R&d Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Xinwei Low Carbon Technology R&d Co ltd filed Critical Hangzhou Xinwei Low Carbon Technology R&d Co ltd
Priority to CN202111203395.1A priority Critical patent/CN113769073A/en
Publication of CN113769073A publication Critical patent/CN113769073A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22004—Bromelain (3.4.22.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a method for treating fundus hemorrhage by using biological enzyme. More specifically, the method comprises the steps of injecting a biological enzyme preparation into the vitreous body of the eye of a patient at regular time and fixed quantity according to the bleeding amount of the ocular fundus of the patient to hydrolyze red blood cells, white blood cells, blood platelets and blood proteins, decomposing the biological enzyme preparation into small molecular substances by using biological enzyme to promote self absorption, realizing the rapid vitreous body transparency recovery and accelerating the healing of the ocular fundus bleeding, and meanwhile, hydrolysate such as peptides, amino acids and the like has medicinal and nutritive values for the eye. Wherein the biological enzyme preparation comprises a proteolytic enzyme, a solvent therefor and a container. The invention can greatly accelerate the rehabilitation of the patient with fundus hemorrhage by matching with fundus laser treatment, and is very beneficial to the rapid recovery of the vision of the patient.

Description

Method for treating fundus hemorrhage by using biological enzyme
Technical Field
The invention relates to a method for treating fundus hemorrhage by using biological enzyme, belonging to the fields of medicines, preparations and the like.
Technical Field
The main manifestations of fundus hemorrhage are blood accumulation in eyes caused by retinal hemorrhage, common symptoms are that black shadow floats in front of eyes, objects in the center area are unclear, vision is lost, suddenly a piece of black shadow in front of eyes is blocked and does not float along with the rotation of eyes, objects on the center area are completely invisible, objects on two sides are fuzzy and visible, wired strip-shaped black shadow is directly projected to a certain direction and gradually added, and finally, the front of eyes are covered, red light flickers appear in front of eyes and gradually added, so that the eyes are full of red light and the like. Patients with fundus hemorrhage are mostly diabetic patients and patients with macular degeneration. Eyeground hemorrhage seriously affects the life of patients, the treatment is long, and the clearance of the hematocele is basically absorbed slowly by the patient.
At present, the main treatment method of fundus hemorrhage is surgical excision of vitreous body, and the internal medicine method is basically absent. Surgical removal of the vitreous is highly damaging to the eye, multiple surgeries cannot be performed, and the surgery is expensive. As can be seen, no good treatment method for fundus hemorrhage exists at present.
The method for treating the fundus hemorrhage by using the biological enzyme can quickly eliminate the hematocele in the vitreous body, promote the absorption of the hematocele, realize the quick recovery of the vitreous body to be transparent, simultaneously hydrolysate, such as peptides and amino acid, has medicinal and nutritional values for eyes, and can effectively prevent the rebleeding and quickly promote the self absorption of the hematocele in the vitreous body by matching with laser treatment.
Disclosure of Invention
The method for treating fundus hemorrhage by using the biological enzyme has the characteristics of quickly promoting the absorption of vitreous blood and nourishing eyes.
A method for treating the hemorrhage of eyeground by biologic enzyme includes such steps as quantitatively injecting biologic enzyme preparation to the vitreous body of patient's eye to hydrolyze red blood cells, white blood cells, thrombocytes and blood protein, decomposing them into small molecular substance by biologic enzyme for promoting self-absorption, quickly restoring the vitreous body to become transparent, and accelerating the healing of the hemorrhage of eyeground.
A method for treating fundus hemorrhage by using biological enzyme, wherein the biological enzyme preparation comprises proteolytic enzyme, a solvent and a container.
A method for treating fundus hemorrhage by using biological enzyme comprises peptides containing 2-5 amino acids.
A method for treating fundus hemorrhage by using biological enzyme, wherein the proteolytic enzyme includes but is not limited to one or more of collagenase, cathepsin, trypsin, bromelain and papain.
A method for treating fundus hemorrhage by using biological enzyme, wherein the solvent is a sterile solution which simulates the salinity, PH and osmotic pressure of vitreous body and meets the requirement of the activity of proteolytic enzyme.
The specific implementation mode is as follows:
the present invention will be further described with reference to specific embodiments, but the embodiments of the present invention are not limited to the following examples.
Embodiment 1 a method for treating fundus hemorrhage using bio-enzyme, the method comprising the steps of:
1) taking 0.5mL of 1mg/mL cathepsin preparation;
2) sucking 0.5mL of cathepsin preparation by using a special vitreous injector, and injecting the cathepsin preparation into the vitreous body of the hematocele;
3) one injection is injected every 12h, and 3 times are a treatment course;
4) the cathepsin promotes the absorption of fundus hematocele by degrading red blood cells, white blood cells and platelets, thereby realizing the treatment of vitreous hematocele.
Embodiment 2 a method for treating fundus hemorrhage using bio-enzyme, the method comprising the steps of:
1) taking 100IU/mL bromelain preparation, and taking 0.2mL bromelain preparation;
2) sucking 0.2mL of bromelain preparation by using a special vitreous injector, and injecting the bromelain preparation into the vitreous body of the hematocele;
3) one injection is injected every 12h, and 4 times are taken as a treatment course;
4) the bromelain can promote the absorption of fundus hematocele by degrading red blood cells, white blood cells and platelets, thereby realizing the treatment of vitreous hematocele.
Embodiment 3 a method for treating fundus hemorrhage using bio-enzyme, the method comprising the steps of:
1) taking 0.1mL of trypsin preparation with the concentration of 0.05 percent and 0.2mL of cathepsin preparation with the concentration of 0.2 mg/mL;
2) sucking the trypsin and cathepsin preparation by a special vitreous injector, and injecting the trypsin and cathepsin preparation into the vitreous body of the hematocele;
3) the injection is injected once every 24 hours, and 3 times are a treatment course;
4) the trypsin and the cathepsin promote the absorption of fundus hematocele by degrading red blood cells, white blood cells and blood platelets, thereby realizing the treatment of vitreous hematocele.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that the foregoing and other changes, omissions and deviations in the form and detail thereof may be made without departing from the scope of this invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.

Claims (5)

1. A method for treating fundus hemorrhage by using biological enzyme is characterized in that the method comprises the steps of regularly and quantitatively injecting biological enzyme preparation into the vitreous body of the eye of a patient according to the amount of the fundus hemorrhage to hydrolyze red blood cells, white blood cells, platelets and blood proteins, decomposing the biological enzyme preparation into small molecular substances by using the biological enzyme to promote self absorption, realizing rapid vitreous body transparency recovery and accelerating the healing of fundus hemorrhage.
2. A method as claimed in claim 1, wherein the biological enzyme preparation comprises proteolytic enzyme, solvent and container.
3. A method as claimed in claim 1, wherein said small molecule substance includes peptides having 2-5 amino acids.
4. A method as claimed in claim 1 or claim 2, wherein said proteolytic enzymes include but are not limited to one or more of collagenase, cathepsin, trypsin, bromelain and papain in combination.
5. A method for treating fundus hemorrhage using bio-enzyme according to claim 1 or 2, wherein said solvent is a sterile solution simulating vitreous salinity, PH, osmotic pressure and satisfying the requirement of proteolytic enzyme activity.
CN202111203395.1A 2021-10-15 2021-10-15 Method for treating fundus hemorrhage by using biological enzyme Pending CN113769073A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111203395.1A CN113769073A (en) 2021-10-15 2021-10-15 Method for treating fundus hemorrhage by using biological enzyme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111203395.1A CN113769073A (en) 2021-10-15 2021-10-15 Method for treating fundus hemorrhage by using biological enzyme

Publications (1)

Publication Number Publication Date
CN113769073A true CN113769073A (en) 2021-12-10

Family

ID=78873176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111203395.1A Pending CN113769073A (en) 2021-10-15 2021-10-15 Method for treating fundus hemorrhage by using biological enzyme

Country Status (1)

Country Link
CN (1) CN113769073A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207684A (en) * 1995-11-22 1999-02-10 先进角膜系统公司 Enzymatic method and compositions for treating intravitreal hemorrhagic blood
CN101171030A (en) * 2005-05-11 2008-04-30 博士伦公司 Use of plasmin for preventing of reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CN101204579A (en) * 2006-12-14 2008-06-25 复旦大学 Application of regrouped human minute plasminogen on process for preparing the medicine curing eye disorders
CN101422603A (en) * 2007-10-31 2009-05-06 马万超 Insoluble biological activity protein as vitreous body oral medicine for treating ophthalmic diseases
CN101505790A (en) * 2006-08-16 2009-08-12 马林大药厂 Treatment of ocular diseases
CN104869990A (en) * 2012-10-17 2015-08-26 布里斯托大学 Compounds useful for treating ocular neovasculan

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1207684A (en) * 1995-11-22 1999-02-10 先进角膜系统公司 Enzymatic method and compositions for treating intravitreal hemorrhagic blood
CN101171030A (en) * 2005-05-11 2008-04-30 博士伦公司 Use of plasmin for preventing of reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CN101505790A (en) * 2006-08-16 2009-08-12 马林大药厂 Treatment of ocular diseases
CN101204579A (en) * 2006-12-14 2008-06-25 复旦大学 Application of regrouped human minute plasminogen on process for preparing the medicine curing eye disorders
CN101422603A (en) * 2007-10-31 2009-05-06 马万超 Insoluble biological activity protein as vitreous body oral medicine for treating ophthalmic diseases
CN104869990A (en) * 2012-10-17 2015-08-26 布里斯托大学 Compounds useful for treating ocular neovasculan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈辰等: "注射用胰蛋白酶生产控制策略", 上海医药, vol. 39, no. 13, pages 87 *

Similar Documents

Publication Publication Date Title
JP5620640B2 (en) Improved botulinum toxin composition
ES2275992T3 (en) BOTULINIC TOXIN PHARMACEUTICAL CDOMPOSITIONS.
Zhang et al. Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates
ES2281636T5 (en) USE OF BOTULINIC TOXIN TO TREAT CARDIOVASCULAR DISEASES.
EP1824775B1 (en) Debriding composition from bromelain and methods of production thereof
US8216591B2 (en) Pharmaceutical compositions containing botulinum toxin
FI85334C (en) Process for Preparation of an Aqueous Tissue Plasminogenic Tivator (t-PA) Containing Concentrated Parent Solution
EP2621520B1 (en) Collagenase g and collagenase h compositions for the treatment of diseases involving alterations of collagen
CN101175478A (en) Non-protein stabilized clostridial toxin pharmaceutical compositions
EP0124018B1 (en) Pharmaceutical preparation containing purified fibronectin
CN113769073A (en) Method for treating fundus hemorrhage by using biological enzyme
CN101422603A (en) Insoluble biological activity protein as vitreous body oral medicine for treating ophthalmic diseases
JPWO2006025276A1 (en) Treatment and prevention agent for ophthalmic diseases including nattokinase
JPH06135851A (en) Chondroitinase composition and preparation for injection containing the same composition
ES2732659T3 (en) Resorption enhancers as additives to improve oral formulation of low molecular weight heparins
CN1488399A (en) Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease
WO2023089906A1 (en) Leakage inhibiting agent for local injection, local injection containing same, and method for producing local injection
KR20240095404A (en) Leakage inhibitor for topical injection, topical injection comprising the same, and method for producing the topical injection
CN1148504A (en) Fibrin freeze-dried drops and preparation method thereof
WO1999000141A1 (en) Use of bromelain in the manufacture of a medicament for enhancement of intestinal permeability
Rangari Protein Containing Drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination